(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 October 2020 (15.10.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/208177 A1

(51) International Patent Classification:
C07K 16/42 (2006.01) *A61P 37/08* (2006.01)
A61P 11/06 (2006.01)

(21) International Application Number:
PCT/EP2020/060240

(22) International Filing Date:
09 April 2020 (09.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1905150.7 11 April 2019 (11.04.2019) GB

(71) Applicant: **ARGENX BVBA** [BE/BE]; Industriepark Zwijnaarde 7, B-9052 Gent (BE).

(72) Inventors: **SAUNDERS, Michael**; Industriepark Zwijnaarde 7, B-9052 Gent (BE). **BIGIRIMANA, Rene**; Industriepark Zwijnaarde 7, B-9052 Gent (BE). **BLANCHETOT, Christophe**; Industriepark Zwijnaarde 7, B-9052 Gent (BE). **CROMHEEKE, Marijn**; Industriepark Zwijnaarde 7, B-9052 Gent (BE). **MCGUIRE, Conor**; Industriepark Zwijnaarde 7, B-9052 Gent (BE).

(74) Agent: **BOULT WADE TENNANT LLP**; Salisbury Square House, 8 Salisbury Square, London Greater London EC4Y 8AP (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-IgE ANTIBODIES

Fig. 1



(57) Abstract: The present invention relates to antibodies that bind to IgE and their use in the treatment of autoimmune diseases, particularly Bullous Pemphigoid (BP) and Chronic Spontaneous Urticaria (CSU). The anti-IgE antibodies comprise a variant Fc domain that binds to the Fc receptor FcRn with increased affinity relative to a wild-type Fc domain. The anti-IgE antibodies may comprise a variant Fc domain comprising the amino acids Y, T, E, K, F and Y at EU positions 252, 254, 256, 433, 434 and 436, respectively, wherein the variant Fc domain binds to human FcRn with increased affinity relative to a wild-type human IgG Fc domain.

WO 2020/208177 A1

[Continued on next page]

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*